

¹⁸
~~2~~. (Twice Amended) The method according to claim ¹⁷~~1~~, wherein the drug-resistant hypercalcemia is resistant to a therapeutic agent for hypercalcemia other than said at least one substance that inhibits the binding between PTHrP and a receptor thereof.

¹⁹
~~3~~. (Twice Amended) The method according to claim ¹⁸~~2~~, wherein the therapeutic agent for hypercalcemia is chosen from at least one of a bone resorption-inhibiting agent, a calcium excretion-promoting agent, an agent for inhibiting intestinal absorption of calcium, and a loop diuretic.

²⁰
~~4~~. (Amended) The method according to claim ¹⁸~~2~~, wherein the therapeutic agent for hypercalcemia is a bone resorption-inhibiting agent.

²¹
~~5~~. (Twice Amended) The method according to claim ²⁰~~4~~, wherein the bone resorption-inhibiting agent is at least one of bisphosphonate or calcitonin.

²²
~~6~~. (Twice Amended) The method according to any one of claims ¹⁷~~1~~ or ¹⁸~~2~~, wherein said at least one substance is an antagonist of the PTHrP receptor.

²³
~~7~~. (Twice Amended) The method according to any one of claims ¹⁷~~1~~ or ¹⁸~~2~~, wherein said at least one substance is an anti-PTHrP antibody.

²⁴
~~8~~. (Twice Amended) The method according to any one of claims ¹⁷~~1~~ or ¹⁸~~2~~, wherein said at least one substance is a fragment of an anti-PTHrP antibody or a modified form of the fragment.

²⁵
~~9~~. (Amended) The method according to claim ²³~~7~~, wherein the antibody is monoclonal.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

²⁶
~~10~~. (Twice Amended) The method according to claim ²³~~7~~, wherein the antibody is chosen from at least one of a human antibody, a humanized antibody, and a chimeric antibody.

²⁷
~~11~~. (Amended) The method according to claim ²³~~7~~, wherein the antibody is in a humanized form.

²⁸
~~12~~. (Amended) The method according to claim ²⁷~~11~~, wherein the humanized antibody is humanized #23-57-137-1 antibody.

²⁹
~~13~~. (Twice Amended) The method according to any one of claims ¹⁷~~7~~ or ¹⁸~~2~~, wherein the drug-resistant hypercalcemia is caused by cancer.

³⁰
~~14~~. (Amended) The method according to claim ²¹~~5~~, wherein said at least one substance is chosen from at least one of

- a) an antagonist of the PTHrP receptor;
- b) an anti-PTHrP antibody; and
- c) a fragment of an anti-PTHrP antibody or a modified form of the fragment.

³¹
~~15~~. (Amended) The method of claim ³⁰~~14~~, wherein the antibody is chosen from at least one of a human antibody, a humanized antibody, and a chimeric antibody.

³²
~~16~~. (Amended) The method according to claim ²¹~~5~~, wherein the drug-resistant hypercalcemia is caused by cancer.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com